QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

May 26, 2021 Auto Bot MedTech, Mirati, Non-Small Cell Lung Cancer, NSCLC, Qiagen 0

Shots:

  • The companies collaborated to develop a tissue based KRAS Cdx test to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, which is an investigational small molecule inhibitor of KRASG12
  • The agreement initially focuses on developing CDx for NSCLC and allows to further development of tests for Mirati’s oncology programs
  • The planned CDx would be a part of QIAGEN’s therascreen KRAS testing portfolio based on real-time qualitative PCR for the QIAGEN Rotor-Gene Q MDx instrument. Earlier, the companies collaborated to develop a CDx test to support glesatinib

Click here to­ read full press release/ article | Ref: Businesswire | Image: Reuters

The post QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer first appeared on PharmaShots.